ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2024 Summary: FL Highlights

2024 ASH Annual Meeting Insights Hub

P. Strati

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

FL Updates: Is There a Standard 1L Treatment?

SOHO Brazil 2024

B. Kahl

ASH 2025 Review: Key Trials and Takeaways in 1L and R/R Follicular L…

University of Colorado Division of Hematology

T. Phillips

Standards of Care and Future Directions in FL

Martin Dreyling

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Tandem 2025 Insights: Clinical Practice Recommendations for HCT and …

Insights from 2025 Tandem Annual Meeting

M. Iqbal

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Tazemetostat in Older Frail Adults With Follicular Lymphoma

Erin Mulvey